Related Experiment Video

Updated: Aug 9, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Natural human interferon alpha may act differently when given parenterally or orally to patients chronically infected

J A Georgiades1

  • 1Georgiades Foundation for Therapy of Chronic Diseases, Stafford, TX 77477, USA.

Archivum Immunologiae Et Therapiae Experimentalis
|January 1, 1996
PubMed

Insights

Parenteral interferon alpha (IFN-alpha) for chronic hepatitis B virus (HBV) infection caused metabolic inhibition and adverse effects. Oral nHuIFN-alpha showed improved efficacy and safety, suggesting distinct antiviral mechanisms.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis B virus (HBV) infection poses a significant global health challenge.
  • Interferon alpha (IFN-alpha) is a therapeutic agent used in HBV treatment.
  • Understanding the mechanisms and outcomes of different administration routes is crucial.

Purpose of the Study:

  • To compare the efficacy and safety of parenteral versus oral natural human interferon alpha (nHuIFN-alpha) in chronic HBV patients.
  • To investigate the impact of different IFN-alpha administration routes on cellular metabolism and adverse reactions.
  • To evaluate the long-term outcomes regarding HBV-e antigen (HBV-BeAg) loss and seroconversion.

Main Methods:

  • Literature review of patients with chronic HBV infection treated with parenteral or oral nHuIFN-alpha.
  • Analysis of reported effects on cellular metabolism, blood counts, and adverse reactions.
  • Comparison of HBV-BeAg loss and seroconversion rates between treatment groups over two years.

Main Results:

  • Parenteral nHuIFN-alpha (5 x 10(6) IU daily) inhibited cellular metabolism, reduced blood elements, and caused adverse reactions.
  • Oral nHuIFN-alpha did not induce metabolic block or adverse reactions, even with prolonged therapy.
  • Two-year outcomes: Parenteral IFN-alpha achieved 53.8% HBV-BeAg loss and 28.8% seroconversion; oral IFN-alpha achieved 77% HBV-BeAg loss and 74% seroconversion.

Conclusions:

  • Oral nHuIFN-alpha demonstrates superior efficacy and safety compared to parenteral administration for chronic HBV.
  • The distinct outcomes suggest that oral and parenteral nHuIFN-alpha activate different mechanisms for viral elimination.
  • Further research into these differential mechanisms could optimize HBV treatment strategies.

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Concept Videos

Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...